↓ Skip to main content

Cochrane Database of Systematic Reviews

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

Overview of attention for article published in this source, October 2013
Altmetric Badge

Mentioned by

2 tweeters
2 Wikipedia pages


22 Dimensions

Readers on

114 Mendeley
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer
Published by
John Wiley & Sons, Ltd, October 2013
DOI 10.1002/14651858.cd010482.pub2
Pubmed ID

Lawrie, Theresa A, Rabbie, Roy, Thoma, Clemens, Morrison, Jo


Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first-line management. Currently, the recommended standard first-line chemotherapy is platinum-based, usually consisting of carboplatin and paclitaxel (PAC/carbo). Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin that is associated with fewer and less severe side effects than are seen with non-modified doxorubicin. In combination with carboplatin, PLD has recently been shown to improve progression-free survival compared with PAC/carbo in women with relapsed, platinum-sensitive EOC. It is therefore important to know whether any survival benefit can be attributed to PLD when it is used in the first-line setting.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Canada 1 <1%
Unknown 112 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 15%
Researcher 14 12%
Student > Ph. D. Student 14 12%
Student > Master 12 11%
Other 9 8%
Other 17 15%
Unknown 31 27%
Readers by discipline Count As %
Medicine and Dentistry 44 39%
Nursing and Health Professions 10 9%
Pharmacology, Toxicology and Pharmaceutical Science 7 6%
Psychology 5 4%
Biochemistry, Genetics and Molecular Biology 3 3%
Other 10 9%
Unknown 35 31%